Apollo Eyes JNJ Orthopedics Unit in $20 Billion Deal

Johnson & Johnson's (JNJ) orthopedics unit has been in the spotlight recently, with Apollo Global Management reportedly eyeing a potential acquisition of the business. The deal could be worth around $20 billion and would likely unlock significant value for shareholders.

The news sent JNJ's stock up by 2% last week, but some investors are tempering their enthusiasm due to a recent phase 2 trial miss for one of the company's depression drug candidates partnered with Contineum. Analysts on social media are weighing in on the impact this setback will have on the company's pipeline.

Despite this hiccup, JNJ's long-term performance remains impressive. The stock has outperformed the S&P 500 over the past 15 years and is seen as a stable healthcare play amidst market volatility.